Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 3
2015 2
2016 1
2017 4
2018 3
2019 5
2020 5
2021 5
2022 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Antibody Isotypes for Tumor Immunotherapy.
Kretschmer A, Schwanbeck R, Valerius T, Rösner T. Kretschmer A, et al. Among authors: rosner t. Transfus Med Hemother. 2017 Sep;44(5):320-326. doi: 10.1159/000479240. Epub 2017 Sep 7. Transfus Med Hemother. 2017. PMID: 29070977 Free PMC article. Review.
Complement in antibody-based tumor therapy.
Derer S, Beurskens FJ, Rosner T, Peipp M, Valerius T. Derer S, et al. Among authors: rosner t. Crit Rev Immunol. 2014;34(3):199-214. doi: 10.1615/critrevimmunol.2014009761. Crit Rev Immunol. 2014. PMID: 24941073 Review.
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.
Vogiatzi F, Heymann J, Müller K, Winterberg D, Drakul A, Rösner T, Lenk L, Heib M, Gehlert CL, Cario G, Schrappe M, Claviez A, Bornhauser B, Bourquin JP, Bomken S, Adam D, Frielitz FS, Maecker-Kolhoff B, Stanulla M, Valerius T, Peipp M, Kellner C, Schewe DM. Vogiatzi F, et al. Among authors: rosner t. Blood Adv. 2022 Aug 23;6(16):4847-4858. doi: 10.1182/bloodadvances.2022007364. Blood Adv. 2022. PMID: 35820018 Free PMC article.
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL.
Müller K, Vogiatzi F, Winterberg D, Rösner T, Lenk L, Bastian L, Gehlert CL, Autenrieb MP, Brüggemann M, Cario G, Schrappe M, Kulozik AE, Eckert C, Bergmann AK, Bornhauser B, Bourquin JP, Valerius T, Peipp M, Kellner C, Schewe DM. Müller K, et al. Among authors: rosner t. Blood. 2022 Jul 7;140(1):45-57. doi: 10.1182/blood.2021014485. Blood. 2022. PMID: 35452517 Free article.
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T, Lutz S, Münnich IA, Windisch R, Hilger P, Herold T, Tahiri N, Banck JC, Weigert O, Moosmann A, von Bergwelt-Baildon M, Flamann C, Bruns H, Wichmann C, Baumann N, Valerius T, Schewe DM, Peipp M, Rösner T, Humpe A, Kellner C. Zeller T, et al. Among authors: rosner t. Front Immunol. 2022 Oct 27;13:929339. doi: 10.3389/fimmu.2022.929339. eCollection 2022. Front Immunol. 2022. PMID: 36389667 Free PMC article.
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.
Baumann N, Arndt C, Petersen J, Lustig M, Rösner T, Klausz K, Kellner C, Bultmann M, Bastian L, Vogiatzi F, Leusen JHW, Burger R, Schewe DM, Peipp M, Valerius T. Baumann N, et al. Among authors: rosner t. Front Immunol. 2022 Aug 16;13:949140. doi: 10.3389/fimmu.2022.949140. eCollection 2022. Front Immunol. 2022. PMID: 36052078 Free PMC article.
Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
Heemskerk N, Gruijs M, Temming AR, Heineke MH, Gout DY, Hellingman T, Tuk CW, Winter PJ, Lissenberg-Thunnissen S, Bentlage AE, de Donatis M, Bögels M, Rösner T, Valerius T, Bakema JE, Vidarsson G, van Egmond M. Heemskerk N, et al. Among authors: rosner t. J Clin Invest. 2021 Mar 15;131(6):e134680. doi: 10.1172/JCI134680. J Clin Invest. 2021. PMID: 33561014 Free PMC article.
CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma.
Valerius T, Rösner T, Leusen JHW. Valerius T, et al. Among authors: rosner t. N Engl J Med. 2019 Jan 31;380(5):496-7. doi: 10.1056/NEJMc1816156. N Engl J Med. 2019. PMID: 30702240 No abstract available.
Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.
Gehlert CL, Rahmati P, Boje AS, Winterberg D, Krohn S, Theocharis T, Cappuzzello E, Lux A, Nimmerjahn F, Ludwig RJ, Lustig M, Rösner T, Valerius T, Schewe DM, Kellner C, Klausz K, Peipp M. Gehlert CL, et al. Among authors: rosner t. Front Immunol. 2022 Aug 31;13:957874. doi: 10.3389/fimmu.2022.957874. eCollection 2022. Front Immunol. 2022. PMID: 36119088 Free PMC article.
Immune Effector Functions of Human IgG2 Antibodies against EGFR.
Rösner T, Kahle S, Montenegro F, Matlung HL, Jansen JHM, Evers M, Beurskens F, Leusen JHW, van den Berg TK, Valerius T. Rösner T, et al. Mol Cancer Ther. 2019 Jan;18(1):75-88. doi: 10.1158/1535-7163.MCT-18-0341. Epub 2018 Oct 3. Mol Cancer Ther. 2019. PMID: 30282813
30 results